LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...
Sanofi-Aventis has received approval from US regulators for expanded use of its blockbuster anticoagulant Lovenox as a treatment for severe heart attacks. Sanofi-Aventis has received approval from US ...
SAN FRANCISCO (MarketWatch) -- The Food and Drug Administration on Friday said it approved the first generic version of Sanofi-Aventis SA's blood thinner Lovenox. Novartis AG's generic drug unit ...
Sanofi-Aventis is suing FDA, claiming the agency acted inconsistently and unlawfully in approving a generic version of its anticoagulant Lovenox. The approval of the generic, developed by Momenta ...
Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback